Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Prolonged or high-dose oestrogen exposure, particularly via oral contraceptives, has been associated with intrahepatic cholestasis and hepatocellular adenoma (HCA), especially in predisposed individuals.

• Oral contraceptives represent a specific risk context for both intrahepatic cholestasis and HCA development.
• Genetic predisposition is identified as a modulating factor in these adverse hepatic outcomes.
• The association is particularly noted with prolonged or high-dose oestrogen exposure rather than short-term or low-dose use.

Hormone replacement therapy in postmenopausal women is generally safe and may confer metabolic and hepatic benefits.

• This finding contrasts with the risks associated with oral contraceptives, suggesting a different risk profile for postmenopausal hormonal therapy.
• The authors characterize HRT as 'generally safe' in this population.
• Potential metabolic and hepatic benefits were identified as part of the HRT risk-benefit profile.

Oestrogens appear to slow fibrosis progression and reduce hepatocellular carcinoma risk.

• The protective role of oestrogens contrasts with the disease-promoting effects of androgens.
• This finding suggests a sex-hormone-mediated differential in liver disease trajectory.
• The review characterizes oestrogens as 'often protective' in the context of hepatic physiology and disease processes.

Androgens can promote steatosis and HBV-related oncogenesis.

• Androgens are described as tending to 'worsen disease progression' in the liver.
• Two specific mechanisms identified are promotion of hepatic steatosis and facilitation of HBV-related oncogenesis.
• This androgen-mediated effect is framed as distinct from and opposite to oestrogenic effects on the liver.

Hormonal therapies are safe in most patients with compensated chronic liver disease but require caution in polycystic liver disease, where oestrogens can accelerate cyst growth.

• Compensated chronic liver disease is identified as a context where hormonal therapies are generally safe.
• Polycystic liver disease is highlighted as a specific exception requiring caution.
• Oestrogen-mediated acceleration of cyst growth is the mechanism of concern in polycystic liver disease.
• The distinction between compensated and other forms of liver disease is emphasized as clinically relevant.

Emerging data indicate a role of sex hormones in autoimmune and cholestatic diseases, as well as in outcomes of assisted reproduction and gender-affirming therapy.

• The paper reviews evidence on assisted reproductive technology (ART) in the context of liver disease.
• Gender-affirming hormonal treatments are included as an area of active investigation.
• Both autoimmune liver diseases and cholestatic diseases are identified as conditions where sex hormone interplay is relevant.
• The authors describe these as 'emerging data,' indicating an evolving rather than established evidence base.

The liver is central to sex hormone metabolism, and sex hormones in turn modulate hepatic physiology and disease processes.

• This bidirectional relationship forms the conceptual basis of the review.
• The paper positions the liver as both a metabolic site for sex hormones and a target of their action.
• This relationship has implications for how liver disease may alter hormone levels and how hormonal therapies may affect liver disease.